Frontier Biotechnologies Inc. (SHA:688221)

Market Cap	6.48B
Revenue (ttm)	133.15M
Net Income (ttm)	-189.80M
Shares Out	374.58M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,219,469
Average Volume	21,029,163
Open	17.97
Previous Close	17.88
Day's Range	17.50 - 18.26
52-Week Range	4.48 - 24.67
Beta	0.92
RSI	42.11
Earnings Date	Aug 30, 2025

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health in China. The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products in development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dys...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 302
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688221

Financial Performance

In 2024, Frontier Biotechnologies's revenue was 129.47 million, an increase of 13.32% compared to the previous year's 114.25 million. Losses were -201.38 million, -38.78% less than in 2023.